Patterson R, Harris K E, Handley D A, Saunders R N
Department of Medicine, Northwestern University Medical School, Chicago, IL 60611.
J Lab Clin Med. 1987 Nov;110(5):606-11.
An acute airway response to aerosolized platelet activating factor (PAF) can be induced in certain rhesus monkeys. This PAF airway response is completely inhibited by the PAF antagonist, SRI 63-441, in normal monkeys. After the completion of these studies showing inhibition of the PAF airway response, we evaluated whether the PAF antagonist could inhibit three types of acute IgE-mediated airway responses to Ascaris suum (A) in rhesus monkeys. The A aerosol test protocols used the following: a single A aerosol challenge system; a threshold dose of A challenge system, which consists of increasing A aerosol exposure until an airway response occurs; and two sequential A challenges in which the response to the second A challenge always occurs if there is a response to the first A challenge. When SRI 63-441 was tested as a potential antagonist of the A airway response in any of these three systems, no inhibition was shown.
在某些恒河猴中可诱导出对雾化血小板活化因子（PAF）的急性气道反应。在正常猴子中，这种PAF气道反应可被PAF拮抗剂SRI 63 - 441完全抑制。在完成这些显示PAF气道反应受到抑制的研究后，我们评估了PAF拮抗剂是否能抑制恒河猴中三种类型的急性IgE介导的对猪蛔虫（A）的气道反应。A气溶胶测试方案如下：单一A气溶胶激发系统；阈值剂量的A激发系统，该系统包括增加A气溶胶暴露直至出现气道反应；以及两次连续的A激发，如果对第一次A激发有反应，那么对第二次A激发总会出现反应。当在这三种系统中的任何一种中测试SRI 63 - 441作为A气道反应的潜在拮抗剂时，均未显示出抑制作用。
